Edgewise Therapeutics reports positive updates from HCM drug EDG-7500
CIRRUS-HCM, an open-label, multi-part study, evaluates EDG-7500 in patients with obstructive and nonobstructive HCM
CIRRUS-HCM, an open-label, multi-part study, evaluates EDG-7500 in patients with obstructive and nonobstructive HCM
Wayrilz represents a new approach to ITP by targeting the disease at its root through multi-immune modulation
TactiFlex, the world’s first catheter with a flexible tip and contact?force sensing, allows doctors to deliver energy precisely and safely.
The seminar aimed to raise public awareness about inflammageing—chronic, low-grade inflammation that silently damages the body and accelerates ageing
The new facility is expected to generate 500-600 new jobs in the region
The company shall process the change of name application with BSE Ltd. in due course
The reform is set to modernise how medicines are developed, authorised, and made available across the EU
Subscribe To Our Newsletter & Stay Updated